loading page

COVID-19 Impact on Pediatric Oncology and Hematology: A Report From the French Society of Pediatric Oncology
  • +11
  • Jérémie GAUDICHON,
  • Eric Thebault,
  • Arthur Felix,
  • Aurélie Phulpin,
  • Catherine Paillard,
  • Aurélia Alimi,
  • Benoît Brethon,
  • Elodie Gouache,
  • Sandra Raimbault,
  • Eva De Berranger,
  • Marilyne Poiree,
  • Séverine Bouttefroy,
  • Nicolas André,
  • Virginie Gandemer
CHU de Caen
Author Profile
Eric Thebault
Gustave Roussy Institute
Author Profile
Arthur Felix
Gustave Roussy Institute
Author Profile
Aurélie Phulpin
CHU Nancy
Author Profile
Catherine Paillard
Hopitaux universitaires de Strasbourg
Author Profile
Aurélia Alimi
Institut Curie
Author Profile
Benoît Brethon
Hôpital Universitaire Robert-Debré
Author Profile
Elodie Gouache
Hopital Armand-Trousseau
Author Profile
Sandra Raimbault
Oscar Lambret Cancer Centre
Author Profile
Eva De Berranger
CHRU Lille
Author Profile
Marilyne Poiree
CHU Nice, Service d'Hématologie Oncologie Pédiatrique
Author Profile
Séverine Bouttefroy
Author Profile
Nicolas André
Hôpital pour enfants de
Author Profile
Virginie Gandemer
CHU Rennes
Author Profile


Introduction: Data regarding coronavirus disease 2019 (COVID-19) description are still limited in pediatric oncology. The French society of pediatric oncology (SFCE) has initiated a study to better describe the presentation and evolution of COVID-19 in patients followed in French pediatric oncology and hematology wards. Methods: All patients diagnosed with COVID-19 (polymerase chain reaction [PCR] positive for severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], or positive IgM serology, or chest computed tomography scan and clinical signs typical of COVID-19) and followed in a SFCE center were enrolled. Data from medical records were analyzed for all patients enrolled up to the end of May 2020. Results: Data was available for 37 patients. Thirty-one were children under 18 years of age. Nineteen patients were female. Seventeen patients had a solid tumor, 16 had a hematological malignancy and four recently underwent hematopoietic stem cell transplantation (HSCT) for non-oncological conditions. Twenty-eight patients presented symptoms, most often with fever, cough, rhinorrhea and asthenia. Ground-glass opacities were the most frequent radiological finding with abnormalities mostly bilateral and peripherally distributed. Twenty-four patients received chemotherapy a month prior to COVID-19 diagnosis. Most patients did not require hospitalization. Three patients required oxygen at the time of diagnosis. In total, five patients were admitted in an intensive care unit because of COVID-19 and one died from the disease. Conclusion: Children and young adults infected with SARS-CoV-2 and treated for a cancer and/or with a HSCT may be at risk for severe COVID-19 and should be closely monitored. (NCT04433871)